Interim Report – January to March 2021

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its First Quarter Report for 2021.

Financial Highlights

• Revenue for the 1st Quarter 2021 amounted to SEK 15.2 (9.6) m
• Operating result for the quarter amounted to SEK -91.9 (-58.2) m
• Net result for the quarter amounted to SEK -93.2 (-58.9) m
• Cash flow for the quarter amounted to SEK -94.6 (-78.4) m
• Cash and cash equivalents at the end of the period amounted to SEK 41.3 (296.4) m

Significant Events during the Reporting Period

• On February 10 2021, Affibody AB and Inmagene Biopharmaceuticals announced that the U.S. FDA has cleared izokibep (ABY-035) to proceed to Phase 2 clinical development in Ankylosing Spondylitis (AS), a subset of Axial Spondyloarthritis (axSpA). 
• On March 9 2021, Affibody AB and Inmagene Biopharmaceuticals announced that the U.S. FDA has cleared the novel interleukin-17 (IL-17) blocker izokibep (ABY-035) to proceed to Phase 2 clinical development in non-infectious intermediate, posterior, and pan-uveitis.

Significant Events after the close of the Reporting Period

• On May 3 2021 Affibody Medical AB (publ) received a SEK 100.0 m loan from its major shareholder Duba AB, a subsidiary within the Investor group.